UB Paderborn / Katalog / Suche / in CDI

Therapeutic targeting of the IL-12/23 pathways: generation and characterization of ustekinumab

Nature biotechnology, 2011-07, Vol.29 (7), p.615-624

2011

Volltextzugriff (PDF)

Abciximab suppresses the rise in levels of circulating inflammatory markers after percutaneous coronary revascularization

Circulation (New York, N.Y.), 2001-07, Vol.104 (2), p.163-167

2001

Volltextzugriff (PDF)

An additional mechanism of action of abciximab: dispersal of newly formed platelet aggregates

Thrombosis and haemostasis, 2002, Vol.87 (6), p.1020

2002

Volltextzugriff (PDF)

Simultaneous modeling of abciximab plasma concentrations and ex vivo pharmacodynamics in patients undergoing coronary angioplasty

The Journal of pharmacology and experimental therapeutics, 2003-12, Vol.307 (3), p.969

2003

Volltextzugriff (PDF)

Pharmacodynamic profile of short-term abciximab treatment demonstrates prolonged platelet inhibition with gradual recovery from GP IIb/IIIa receptor blockade

Circulation (New York, N.Y.), 1998-05, Vol.97 (17), p.1680-1688

1998

Volltextzugriff (PDF)

Rapid assessment of platelet function with a modified whole-blood aggregometer in percutaneous transluminal coronary angioplasty patients receiving anti-GP IIb/IIIa therapy

Circulation (New York, N.Y.), 1997-12, Vol.96 (11), p.3860-3866

1997

Volltextzugriff (PDF)

High levels of platelet inhibition with abciximab despite heightened platelet activation and aggregation during thrombolysis for acute myocardial infarction: Results from TIMI (Thrombolysis In Myocardial Infarction) 14

Circulation (New York, N.Y.), 2000-06, Vol.101 (23), p.2690-2695

2000

Volltextzugriff (PDF)

Effect of Ca2+ chelation on the platelet inhibitory ability of the GPIIb/IIIa antagonists abciximab, eptifibatide and tirofiban

Thrombosis and haemostasis, 2001-03, Vol.85 (3), p.539

2001

Volltextzugriff (PDF)

Pharmacodynamics of abciximab during angioplasty: Comparison to healthy subjects

Clinical pharmacology and therapeutics, 2002-03, Vol.71 (3), p.186-195

2002

Volltextzugriff (PDF)

Abciximab Pharmacodynamic Model with Neural Networks used to Integrate Sources of Patient Variability

Clinical pharmacology and therapeutics, 2004-01, Vol.75 (1), p.60-69

2004

Volltextzugriff (PDF)

Potential future clinical applications for the GPIIb/IIIa antagonist, abciximab in thrombosis, vascular and oncological indications

Pathology oncology research, 2000, Vol.6 (3), p.163-174

2000

Volltextzugriff (PDF)

Abciximab partially attenuates adverse events associated with trombocytopenia: analysis of GUSTO IV ACS

Journal of the American College of Cardiology, 2002-03, Vol.39, p.316-316

2002

Volltextzugriff (PDF)

Pharmacodynamic profile of short-term readministration of abciximab in healthy subjects

The American heart journal, 2002-01, Vol.143 (1), p.87-94

2002

Volltextzugriff (PDF)

Analysis of GPIIb/IIIa Receptor Number by Quantification of 7E3 Binding to Human Platelets

Blood, 1996-08, Vol.88 (3), p.907-914

1996

Volltextzugriff (PDF)

Analysis of GPIIb/IIIa receptor number by quantification of 7E3 binding to human platelets

Blood, 1996-08, Vol.88 (3), p.907-914

1996

Volltextzugriff (PDF)

Ig H and L chain contributions to autoimmune specificities

The Journal of immunology (1950), 1991-01, Vol.146 (1), p.176

1991

Volltextzugriff (PDF)

Proteolytic studies on the structure of bovine von Willebrand factor

Biochemistry (Easton), 1988-02, Vol.27 (4), p.1274-1284

1988

Volltextzugriff (PDF)

Therapeutic heparin concentrations augment platelet reactivity: Implications for the pharmacologic assessment of the glycoprotein IIb/IIIa antagonist abciximab

The American heart journal, 2000-04, Vol.139 (4), p.696-703

2000

Volltextzugriff (PDF)

Abciximab, ticlopidine, and concomitant abciximab-ticlopidine therapy: Ex vivo platelet aggregation inhibition profiles in patients undergoing percutaneous coronary interventions

The American heart journal, 2000-09, Vol.140 (3), p.492-501

2000

Volltextzugriff (PDF)

Therapeutic heparin concentrations augment platelet reactivity: Implications for the pharmacologic assessment of the glycoprotein IIb/IIIa antagonist abciximab

The American heart journal, 2000-04, Vol.139 (4), p.696-703, Article a103229

2000

Volltextzugriff (PDF)

Human monoclonal antibody HA-1A binds to endotoxin via an epitope in the lipid A domain of lipopolysaccharide

The Journal of immunology (1950), 1993-05, Vol.150 (10), p.4438

1993

Volltextzugriff (PDF)

Airway Inflammation and Illness Severity in Response to Experimental Rhinovirus Infection in Asthma

Chest, 2014-06, Vol.145 (6), p.1219-1229

2014

Volltextzugriff (PDF)

Pharmacokinetics and bioavailability of a therapeutic enzyme (idursulfase) in cynomolgus monkeys after intrathecal and intravenous administration

PloS one, 2015-04, Vol.10 (4), p.e0122453-e0122453

2015

Volltextzugriff (PDF)

Mechanisms of Monoclonal Antibody-Drug Interactions

Annual review of pharmacology and toxicology, 2011-01, Vol.51 (1), p.359-372

2011

Volltextzugriff (PDF)

Discovery and mechanism of ustekinumab: A human monoclonal antibody targeting interleukin-12 and interleukin-23 for treatment of immune-mediated disorders

mAbs, 2011-11, Vol.3 (6), p.535-545

2011

Volltextzugriff (PDF)

Menü

Weitere Dienste

Einstellungen

Therapeutic targeting of the IL-12/23 pathways: generation and characterization of ustekinumab

Abciximab suppresses the rise in levels of circulating inflammatory markers after percutaneous coronary revascularization

An additional mechanism of action of abciximab: dispersal of newly formed platelet aggregates

Simultaneous modeling of abciximab plasma concentrations and ex vivo pharmacodynamics in patients undergoing coronary angioplasty

Pharmacodynamic profile of short-term abciximab treatment demonstrates prolonged platelet inhibition with gradual recovery from GP IIb/IIIa receptor blockade

Rapid assessment of platelet function with a modified whole-blood aggregometer in percutaneous transluminal coronary angioplasty patients receiving anti-GP IIb/IIIa therapy

High levels of platelet inhibition with abciximab despite heightened platelet activation and aggregation during thrombolysis for acute myocardial infarction: Results from TIMI (Thrombolysis In Myocardial Infarction) 14

Effect of Ca2+ chelation on the platelet inhibitory ability of the GPIIb/IIIa antagonists abciximab, eptifibatide and tirofiban

Pharmacodynamics of abciximab during angioplasty: Comparison to healthy subjects

Abciximab Pharmacodynamic Model with Neural Networks used to Integrate Sources of Patient Variability

Potential future clinical applications for the GPIIb/IIIa antagonist, abciximab in thrombosis, vascular and oncological indications

Abciximab partially attenuates adverse events associated with trombocytopenia: analysis of GUSTO IV ACS

Pharmacodynamic profile of short-term readministration of abciximab in healthy subjects

Analysis of GPIIb/IIIa Receptor Number by Quantification of 7E3 Binding to Human Platelets

Analysis of GPIIb/IIIa receptor number by quantification of 7E3 binding to human platelets

Ig H and L chain contributions to autoimmune specificities

Proteolytic studies on the structure of bovine von Willebrand factor

Therapeutic heparin concentrations augment platelet reactivity: Implications for the pharmacologic assessment of the glycoprotein IIb/IIIa antagonist abciximab

Abciximab, ticlopidine, and concomitant abciximab-ticlopidine therapy: Ex vivo platelet aggregation inhibition profiles in patients undergoing percutaneous coronary interventions

Therapeutic heparin concentrations augment platelet reactivity: Implications for the pharmacologic assessment of the glycoprotein IIb/IIIa antagonist abciximab

Human monoclonal antibody HA-1A binds to endotoxin via an epitope in the lipid A domain of lipopolysaccharide

Airway Inflammation and Illness Severity in Response to Experimental Rhinovirus Infection in Asthma

Pharmacokinetics and bioavailability of a therapeutic enzyme (idursulfase) in cynomolgus monkeys after intrathecal and intravenous administration

Mechanisms of Monoclonal Antibody-Drug Interactions

Discovery and mechanism of ustekinumab: A human monoclonal antibody targeting interleukin-12 and interleukin-23 for treatment of immune-mediated disorders

Suchergebnisse filtern